Same‐day Hyaluronic Acid rectal spacer for TRUS‐guided HDR Prostate Brachytherapy: Feasibility and dosimetric outcomes
Journal of Applied Clinical Medical Physics · 2026-07 · 27 (7)
DOI: 10.1002/acm2.70701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Clinical Medical Physics, online erschienen am 08.07.2026. Verfasst von Sook Kien Ng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Radiotherapy Planning, Computer-Assisted, Rectum. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Rectal spacers are widely used to reduce rectal dose in prostate radiotherapy. However, their use during transrectal ultrasound (TRUS)‐guided high‐dose‐rate (HDR) brachytherapy has been limited by degradation of ultrasound image quality when placed on the day of the procedure, often necessitating CT‐based planning or separate‐day workflows.
Purpose
To evaluate the feasibility and dosimetric impact of same‐day hyaluronic acid (HA) rectal spacer injection in patients undergoing TRUS‐guided HDR prostate brachytherapy.
Methods
Following institutional review board approval, a retrospective analysis was performed on 20 patients with clinically localized prostate cancer treated with HDR brachytherapy combined with external beam radiation therapy between April 2023 and March 2024. Ten patients with a prostate–anterior rectal wall distance < 5 mm received HA rectal spacer injection immediately prior to HDR brachytherapy, while ten patients with a distance > 5 mm did not undergo spacer placement. HA spacer (3–6 cc) was injected into the perirectal space under sagittal TRUS guidance, followed by catheter placement and real‐time TRUS‐based treatment planning. A single fraction of 15 Gy was delivered. Dosimetric parameters were compared using an unpaired two‐tailed Student's t ‐test.
Results
HA rectal spacer placement was technically successful in all patients (10/10) and preserved ultrasound image quality for catheter placement and treatment planning. Spacer placement improved prostate V100 (95.6% ± 0.5% vs. 94.5% ± 0.6%; p < 0.001) and significantly reduced rectal V75 (0.42 ± 0.25 cc vs. 0.97 ± 0.34 cc; p < 0.001). No significant differences were observed in urethral D10 or bladder D0.1cc.
Conclusions
Same‐day HA rectal spacer injection is feasible during TRUS‐guided HDR prostate brachytherapy and preserves ultrasound image quality, enabling fully real‐time treatment planning without the need for CT‐based workflows. This approach provides rectal dose reduction while maintaining target coverage and may offer a streamlined alternative to multistep spacer placement strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Zitieren
APA
Ng, S. K., Pokhrel, D., Huang, C., Asamoah, F. A., Holmes, J. A., Prabhu, A., & Ishaq, O. (2026). Same‐day Hyaluronic Acid rectal spacer for TRUS‐guided HDR Prostate Brachytherapy: Feasibility and dosimetric outcomes. Journal of Applied Clinical Medical Physics, 27(7). https://doi.org/10.1002/acm2.70701
Vancouver
Ng SK, Pokhrel D, Huang C, Asamoah FA, Holmes JA, Prabhu A, et al. Same‐day Hyaluronic Acid rectal spacer for TRUS‐guided HDR Prostate Brachytherapy: Feasibility and dosimetric outcomes. Journal of Applied Clinical Medical Physics. 2026;27(7). doi:10.1002/acm2.70701
BibTeX
@article{Ng2026,
author = {Ng, Sook Kien and Pokhrel, Damodar and Huang, Colin and Asamoah, Francis Adumata and Holmes, Jordan Alexander and Prabhu, Arpan and Ishaq, Omar},
title = {Same‐day Hyaluronic Acid rectal spacer for TRUS‐guided HDR Prostate Brachytherapy: Feasibility and dosimetric outcomes},
journal = {Journal of Applied Clinical Medical Physics},
year = {2026},
volume = {27},
number = {7},
doi = {10.1002/acm2.70701}
}
EUVIMED